OliX Pharmaceuticals,Inc

KOSDAQ 226950.KQ

OliX Pharmaceuticals,Inc EBITDA Margin for the year ending December 31, 2023: -65.25%

OliX Pharmaceuticals,Inc EBITDA Margin is -65.25% for the year ending December 31, 2023, a 74.87% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

OliX Pharmaceuticals,Inc EBITDA Margin for the year ending December 31, 2022 was -259.70%, a 63.23% change year over year.
OliX Pharmaceuticals,Inc EBITDA Margin for the year ending December 31, 2021 was -706.28%, a 8.41% change year over year.
OliX Pharmaceuticals,Inc EBITDA Margin for the year ending December 31, 2020 was -771.14%, a 35.25% change year over year.
OliX Pharmaceuticals,Inc EBITDA Margin for the year ending December 31, 2019 was -1,191.02%, a 50.04% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

KOSDAQ: 226950.KQ

OliX Pharmaceuticals,Inc

CEO	Mr. Dong-Ki Lee Ph.D.
IPO Date	July 18, 2018
Location	South Korea
Headquarters	#1014 Gwanggyo Ace Tower1, 17
Employees	72
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Eyewear Vaccines

Description

OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer. Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.

Key trends

Past 5 years